- Posted Wednesday February 10, 2010
The Translational Genomics Research Institute (TGen) becomes center of excellence for Horizon Discovery's GENESIS and X-MAN technology
The Translational Genomics Research Institute (TGen) and Horizon
Discovery today announced plans to develop human disease models for
use in TGen's cancer research.
A research-collaboration and sub-licensing agreement will allow TGen investigators to use Horizon's GENESIS™ and X-MAN™ technologies to accelerate the search for new drug targets, biomarkers and anti-cancer agents, which could provide patients with more effective treatments.
Dr. Daniel Von Hoff, TGen's Physician-In-Chief and senior investigator will head the effort at TGen. Dr. Von Hoff is a leading advocate of developing precision cancer therapies. Dr. Von Hoff also is a leader in clinical trial design for agents that are based on an understanding of the cancer genes in patients' tumors.
"TGen is eager to partner with Horizon in the use of these new technologies, which should enhance our research efforts to provide patients with significantly better outcomes,'' Dr. Von Hoff said.
Horizon's core gene-targeting technology and human isogenic cell-lines are expected to enable TGen to create a key center of excellence in translational medicine for generating and applying predictive human disease models in drug discovery.
"Our over-arching mission is to speed up the research, development and prescription of more rational therapies that target the root causes of cancer development in each patient's tumor," said Dr. Chris Torrance, CEO of Horizon, based in Cambridge, U.K. "TGen investigators are visionaries in this respect and we are honored to enable them with Horizon's GENESIS technology to generate a novel pipeline of X-MAN cancer models to support cutting-edge translational oncology research."
Under terms of the collaboration, TGen will use Horizon proprietary technology and know-how to develop a panel of novel cancer cell-lines, which will be licensed back to Horizon for future licensing to the broader academic, biotech and pharma research communities. The parties also have agreed to share, publish and commercialize data from the research program, subject to future commercial terms.
This type of open-source relationship will be replicated in the future by Horizon at selected centers of excellence for translational research with the aim of deciphering the genetic links to cancer and other debilitating diseases.
About Horizon Discovery
Horizon Discovery is a translational genomics and personalised medicine company founded in June 2007 and is headquartered at IQ Cambridge, Cambridge, U.K., and with additional research laboratories in Torino, Italy. Horizon's goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery's offering of X-MAN isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds - a missing link in the rational and efficient development of novel targeted anti-cancer agents. These X-MAN models are now being used to speed up and rationalize every phase of the drug development process; from the discovery of cancer targets and biomarkers to the design of more rational clinical trials based around the patients most likely to respond.
Press Contact: Dr. Darrin M. Disley on +44 (0)1223 303049 or +44 (0)7786 133893 www.horizondiscovery.com
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
TGen Senior Science Writer
# # #